Adenovirus type 4 a

Ended Awarded

Contract number
SPE2DP26F6531
Awardee
Awarding agency
Obligated
$343,526

Award facts

Contract value 100% obligated
$343,526.40 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Firm Fixed Price
Place of performance
Parsippany, NJ 07054, USA

Award details come from SAM.gov/FPDS.

About this award

The Department of Defense Medical Supply Chain issued a $343,526.40 delivery order to Teva Pharmaceuticals Usa, Inc. on June 16, 2026, for Adenovirus Type 4 vaccine, with ultimate completion on June 23, 2026.

The order is firm fixed price with no set-aside. Place of performance is Parsippany, New Jersey. The source does not identify the parent Indefinite Delivery Contract vehicle by its assigned name or number within the delivery order record itself; the GovTribe summary references SPE2DP20D0002 as Teva's primary Adenovirus Type 4 vaccine IDC with DLA Troop Support Medical, but the authoritative parent vehicle designation for this specific order is not explicitly stated in the contract award block.

Quick answers

Who was awarded contract SPE2DP26F6531?

SPE2DP26F6531 was awarded to Teva Pharmaceuticals Usa, Inc. by Medical Supply Chain (Troop Support) on June 16, 2026.

How much is contract SPE2DP26F6531 worth?

The government has obligated $343,526 on SPE2DP26F6531.

Is contract SPE2DP26F6531 an order under another contract?

Yes. SPE2DP26F6531 is a delivery order under SPE2DP20D0002, an indefinite delivery contract.

Was contract SPE2DP26F6531 competed?

The extent of competition for SPE2DP26F6531 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award